Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation
ACS Nano · 2025
DOI: 10.1021/acsnano.5c00985 ↗At a glance
Journal article in ACS Nano, 2025. Written by Hanshu Liu and 8 co-authors. Institution: Department of Infectious Disease and Hepatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Major MEDLINE topics: Liver Cirrhosis, Lysosomes, Transforming Growth Factor beta, Nanoparticles. Cited 23 times so far (Crossref); 48 references. Funded by: Ministry of Science and Technology of the People's Republic of China, Zhengzhou University, National Natural Science Foundation of China.
Abstract (original language)
Liver fibrosis, characterized by excessive extracellular matrix (ECM) deposition, is predominantly driven by activated hepatic stellate cells (HSCs) through the TGF-β-Smad2/3 signaling pathway. A critical barrier to effective treatment has been the compensatory upregulation of the receptors, which often limits the efficacy of targeted TGF-β inhibition strategies. Our current study introduces a lysosomal targeting degradation chimera (MAP) composed of an antioxidative polydopamine (PDA) nanoparticle conjugated to the ligands specifically targeting ALK5, a TGF-β receptor I, and cation-independent mannose 6-phosphate receptor (CI-M6PR). Notably, CI-M6PR is highly upregulated on the surface of the activated HSCs. These MAPs preferentially accumulated in the fibrotic liver tissues, reduced TGF-β production by scavenging reactive oxygen species, and simultaneously recognized the activated HSCs to facilitate targeted lysosomal degradation of ALK5. The interconnected dual-enhanced mechanisms effectively inhibited the TGF-β-Smad2/3 signaling pathway in HSCs, thus diminishing ECM secretion and attenuating liver fibrosis. Together, the current findings, substantiated by in vitro and in vivo studies, demonstrate potent antifibrotic capacities of MAPs, marking an essential advancement in lysosome-targeting degradation technology for liver fibrosis treatment and expanding potential therapeutic options for this intractable condition.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Infectious Disease and Hepatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou 450003, China.
- Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing 100069, China.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, 11 Beiyitiao, Zhongguancun, Beijing 100190,…
ORCID profiles: Yingqiu Qi, Huan Min, Guangjun Nie, Hongxia Liang
Funding
- Ministry of Science and Technology of the People's Republic of China
- Zhengzhou University
- National Natural Science Foundation of China
- Henan Province
- Finance Bureau of Henan Province
Cite
APA
Liu, H., Qi, Y., Wang, L., Zhang, Y., Chen, H., Zhao, Y., Min, H., Nie, G., & Liang, H. (2025). Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation. ACS Nano. https://doi.org/10.1021/acsnano.5c00985
Vancouver
Liu H, Qi Y, Wang L, Zhang Y, Chen H, Zhao Y, et al. Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation. ACS Nano. 2025. doi:10.1021/acsnano.5c00985
BibTeX
@article{Liu2025,
author = {Liu, Hanshu and Qi, Yingqiu and Wang, Longdi and Zhang, Yana and Chen, Hanqing and Zhao, Ying and Min, Huan and Nie, Guangjun and Liang, Hongxia},
title = {Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation},
journal = {ACS Nano},
year = {2025},
doi = {10.1021/acsnano.5c00985}
}
EUVIMED